Viewing Study NCT01660451

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:56 PM
Ignite Modification Date: 2026-01-04 @ 7:51 PM
Study NCT ID: NCT01660451
Status: COMPLETED
Last Update Posted: 2024-07-17
First Post: 2012-08-06
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Sponsor: Bayer
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lymphoma, Non-Hodgkin View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Clinical trial, phase II View
None Phosphatidylinositol 3-Kinase View
None Class I, Non-Hodgkin's lymphoma View